United Therapeutics Corp
UTHRStock
$529.05+81.35%52W
Market Cap$22.58B
P/E16.92x
Div yield—
Beta0.56
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-3.88%
Price vs S&P 500 (4W)-3.60%
VGM Score54.71
Market Capitalization$22.58B
P/E Ratio (Annual)16.92x
Earnings Surprise History
Q1 265.82est. 7.01
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.10
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
UTHRUnited Therapeutics Corp | C | C | C | $529.05 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
United Therapeutics Corp develops and markets therapies for pulmonary arterial hypertension (PAH), a rare and progressive lung disease characterized by elevated blood pressure in the pulmonary arteries. The company's portfolio centers on treprostinil-based treatments, with Tyvaso DPI (inhalation powder) as its primary revenue driver, supported by Remodulin (injection), Orenitram (extended-release tablets), Adcirca (tadalafil), and Unituxin. The U.S. market generates the majority of revenue, though the company maintains a presence in international markets.